Edward Chouchani, PhD, principal investigator of the Chouchani Lab at Dana-Farber Cancer Institute, was one of 18 scientists named as finalists for the 2026 Blavatnik National Awards for Young ...
Longwood Construction Notice: Ongoing construction near our Longwood campus may affect traffic in the area. Check the latest access changes before you travel. If you are a journalist and have a ...
Dr. Hassett received his MD from the Jacobs School of Medicine & Biomedical Sciences at the University at Buffalo and his MPH from the Harvard T.H. Chan Scholl of Public Health. After serving as a ...
The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one ...
At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously ...
Long-term data from a landmark international trial show about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free for 10 years or ...
In a bold step toward addressing the stark disparities in pediatric cancer care, Dana-Farber Cancer Institute is taking the lead in launching IGNITE—the first national, pediatric hematology-oncology ...
Dana-Farber Brigham Cancer Center has been recognized as the Best Hospital for Cancer in Massachusetts and ranked #3 in the nation by U.S. News & World Report. This is the 26th consecutive year ...
Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes ...
A new clinical tool developed by a team of researchers led by the Dana-Farber Cancer Institute identifies which Clonal hematopoiesis patients are at highest risk for cancer progression. Their work was ...
A three-drug treatment combination led to high remission rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer, in a phase 2 clinical trial ...
A large population-based study led by researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Mass General Brigham suggests that genetic testing added to routine newborn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results